From anecdote to targeted therapy: the curious case of thalidomide in multiple myeloma

Cancer Cell. 2014 Jan 13;25(1):9-11. doi: 10.1016/j.ccr.2013.12.019.

Abstract

Thalidomide and related drugs are key drugs for the treatment of multiple myeloma (MM). These agents bind to cereblon, a component of a ubiquitin ligase complex, altering the specificity of the complex to induce the ubiquitylation and degradation of Ikaros (IKZF1) and Aiolos (IKZF3), transcription factors essential for MM growth.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't